Rifaximin SSD

Small molecule

Phase 3topline reported

Evidence outlook · registrational

Topline reported 2026-01

Its supporting mid-stage studies have completed. The sponsor reported topline results in 2026-01 (Phase 3 RED-C programmes (NCT05071716, NCT05297448): both failed their primary endpoints). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Other / comorbidity
NCT05297448 · Bausch Health Americas, Inc.
2022-08-03 – 2026-02-24 · Hepatic Encephalopathy
What this study did
NCT05071716 · Bausch Health Americas, Inc.
2022-04-07 – 2025-12-23 · Hepatic Encephalopathy
What this study did
Phase 2 (3)
Other / comorbidity
NCT03515044 · Bausch Health Americas, Inc.
2018-09-13 – 2020-03-12 · Overt Hepatic Encephalopathy
What this study did
NCT02124512 · Philip Kern
2015-03 – 2019-05-31 · Obese, Insulin Resistance, Metabolic Syndrome
What this study did
NCT01904409 · Bausch Health Americas, Inc.
2013-06 – 2015-07 · Liver Cirrhosis
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT06718686 · Jasmohan Bajaj
2024-12-30 – 2027-12-30 · Dementia Alzheimer Type, Dementia Associated With Cerebrovascular Disease
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rifaximin SSD: this drugPhase 3Small moleculeRifamycin Antibacterialnot yet gradedNo reviewed efficacy summary
Rifaximin (Xifaxan)
Approved(overall)
Small moleculeRifamycin Antibacterialnot yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rifaximin SSD to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
October 2027 (1)
Phase 1/2Dementia Alzheimer Type, Dementia Associated With Cerebrovascular DiseaseRecruiting
Est. primary completion 2027-10-30 · NCT06718686 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Topline resultPhase 3 RED-C programmes (NCT05071716, NCT05297448): both failed their primary endpoints